Skip to main content
AQST
NASDAQ Life Sciences

Aquestive Investor Deck Details $95M Contingent Funding Access Ahead of March 2027 Anaphylm PDUFA

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$3.66
Mkt Cap
$460.017M
52W Low
$2.93
52W High
$6.85
52W Position info
25% above low
Off High info
47% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

AQST sits 25% above its 52-week low of $2.93.

Summary

Aquestive furnished its November 2026 investor presentation, disclosing $90.3 million in cash plus up to $95 million of approval-contingent funding from RTW and Oaktree as it heads toward the March 16, 2027 Anaphylm PDUFA date.


Key Events · Product Development and Regulatory · AQST

  • Investor Deck Furnished Under Item 7.01

    The 8-K contains no transaction or operating announcement; it furnishes the November 2026 corporate presentation as Exhibit 99.1 for institutional investor meetings.

  • Approval-Contingent Funding Access Disclosed

    Presentation cites $90.3 million in cash and cash equivalents as of September 30, 2026, plus potential access to $75 million under a strategic funding agreement with RTW Investments and an additional $20 million under the Oaktree Capital Management debt facility — both subject to conditions including FDA approval of Anaphylm, with no assurance either becomes available.

  • Anaphylm PDUFA Set for March 16, 2027

    The deck reiterates the Class 2 resubmission timeline with a March 16, 2027 PDUFA goal date and targets ex-U.S. filings in Canada by year-end 2026 and the E.U. in Q1 2027.

  • Pipeline Revenue Estimates Restated

    Company estimates potential peak annual net sales of >$1 billion for Anaphylm, >$100 million in potential annual U.S. product sales for Libervant (licensed to Eton), and >$500 million annual revenue for AQST-108 in atopic dermatitis — explicitly not revenue forecasts.


Analysis · AQST · Life Sciences

The 8-K is only a furnishing of the November 2026 investor presentation, but the deck puts hard numbers on how Aquestive funds an Anaphylm launch: $90.3 million of cash at September 30, 2026, plus up to $75 million from RTW Investments and $20 million from the Oaktree facility — both gated on FDA approval of Anaphylm. That is roughly $185 million of potential liquidity against a March 16, 2027 PDUFA goal date, which matters because the company is running a $70.8 million stockholders' deficit and the Q3 print showed revenue falling to $7.6 million. The catch is that the incremental capital is conditional, not committed: if the FDA issues another complete response letter, the funding does not arrive. The deck also frames the commercial case — >$1 billion estimated annual U.S. revenue for Anaphylm, >$100 million potential Libervant sales through Eton, and >$500 million for AQST-108 in atopic dermatitis — all company estimates, not forecasts.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, AQST was trading at $3.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $460M. The 52-week trading range was $2.93 to $6.85. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AQST - Latest Insights

AQST
Nov 03, 2026, 4:19 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $3.80
Real-time Price: $3.54 info
Change: -$0.260 (-7%) info
Market Cap: $445.563M info
AQST
Nov 03, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.69
Real-time Price: $3.54 info
Change: -$0.150 (-4%) info
Market Cap: $445.563M info
AQST
Nov 03, 2026, 4:01 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $3.61
Real-time Price: $3.54 info
Change: -$0.0701 (-2%) info
Market Cap: $445.563M info
AQST
Oct 15, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $4.58
Real-time Price: $3.54 info
Change: -$1.04 (-23%) info
Market Cap: $445.563M info
AQST
Oct 14, 2026, 7:21 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.79
Real-time Price: $3.54 info
Change: -$1.25 (-26%) info
Market Cap: $445.563M info